Edition:
United States

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

3.85USD
21 Jul 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.85
Open
$3.85
Day's High
$3.88
Day's Low
$3.83
Volume
2,692
Avg. Vol
67,375
52-wk High
$5.25
52-wk Low
$1.10

CGIX.OQ

Chart for CGIX.OQ

About

Cancer Genetics, Inc. is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide... (more)

Overall

Beta: 1.27
Market Cap(Mil.): $76.08
Shares Outstanding(Mil.): 19.76
Dividend: --
Yield (%): --

Financials

  CGIX.OQ Industry Sector
P/E (TTM): -- 30.22 15.85
EPS (TTM): -1.16 -- --
ROI: -59.00 7.17 -8.31
ROE: -81.79 11.55 -7.95

BRIEF-Cancer Genetics files for mixed shelf of up to $100 mln

* Cancer Genetics inc files for mixed shelf of up to $100 million - sec filing Source text for Eikon: Further company coverage:

May 25 2017

BRIEF-Cancer Genetics partners with Ventana Medical Systems for market access to predictive biomarker test

* Cancer Genetics, Inc. Partners with Ventana Medical Systems, Inc., a member of the Roche Group, to ensure market access to predictive biomarker test for new immuno-oncology (io) therapy for advanced bladder cancer

May 15 2017

BRIEF-CANCER GENETICS INC REPORTS Q1 LOSS PER SHARE $0.51

* CANCER GENETICS INC ANNOUNCES 15% REVENUE INCREASE IN FIRST QUARTER OF 2017 OVER 2016 ON STRONG ORGANIC GROWTH WHILE CONTINUING ON PATH TO PROFITABILITY

May 11 2017

BRIEF-Cancer Genetics and Mendel.ai announce strategic partnership

* Cancer Genetics, Inc. and Mendel.ai announce strategic partnership enabling artificial intelligence in precision medicine to drive personalized treatment and accelerate clinical trial matching for cancer care

Apr 03 2017

BRIEF-Cancer Genetic Q4 loss per share $0.15

* Cancer Genetics, Inc. Announces record revenue for fourth quarter and full-year 2016 and provides 2017 business update

Mar 23 2017

BRIEF-Cancer Genetics says received approval for a $1 mln gross tax credit from New Jersey technology business tax certificate transfer program

* Cancer Genetics Inc - received approval for a $1.0 million gross tax credit from New Jersey technology business tax certificate transfer program Source text for Eikon: Further company coverage:

Feb 22 2017

BRIEF-CANCER GENETICS LAUNCHES FOCUSED GENOMIC PANEL FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME

* HAS LAUNCHED A FOCUSED GENOMIC PANEL FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME (HBOC)

Jan 25 2017

Competitors

Earnings vs. Estimates